Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: Current state-of-the science

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 249-257

  Sahin, Ibrahim Halil ^a   Hassan, Manal M ^a   Garrett, Christopher R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

COX 2; Gastrointestinal cancers; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; FLUOROURACIL; GEMCITABINE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SULINDAC;

BARRETT ESOPHAGUS; CANCER PREVENTION; CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG MEGADOSE; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; GENETIC REGULATION; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SHORT SURVEY; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

COX-2; GASTROINTESTINAL CANCERS; NSAIDS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84896737676     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.001     Document Type: Review

References (132)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
3. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62:220-241.
4. Kargman S., Charleson S., Cartwright M., Frank J., Riendeau D., Mancini J., Evans J., O'neill G. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996, 111:445-454.
5. Di Rosa M., Giroud J., Willoughby D. Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J. Pathol. 1971, 104:15-29.
6. Seibert K., Masferrer J. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994, 4:17.
7. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908.
8. Crofford L. COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. Supp. 1997, 49:15.
9. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-12.
10. Pasche B. Role of transforming growth factor beta in cancer. J. Cell Physiol. 2001, 186:153-168.
11. Shaheen N., Ransohoff D.F. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer. JAMA 2002, 287:1972-1981.
12. Zimmermann K.C., Sarbia M., Weber A.-A., Borchard F., Gabbert H.E., Schrör K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999, 59:198-204.
13. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., Omary M.B., Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000, 118:487-496.
14. Wilson K.T., Fu S., Ramanujam K.S., Meltzer S.J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 1998, 58:2929-2934.
15. Buskens C.J., Van Rees B.P., Sivula A., Reitsma J.B., Haglund C., Bosma P.J., Offerhaus G., Van Lanschot J., Ristimäki A. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002, 122:1800.
16. Rubio C. Antitumoral activity of indomethacin on experimental esophageal tumors. J. Natl. Cancer Inst. 1984, 72:705-707.
17. Buttar N.S., Wang K.K., Leontovich O., Westcott J.Y., Pacifico R.J., Anderson M.A., Krishnadath K.K., Lutzke L.S., Burgart L.J. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122:1101.
18. Buttar N.S., Wang K.K., Anderson M.A., Dierkhising R.A., Pacifico R.J., Krishnadath K.K., Lutzke L.S. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J. Natl. Cancer Inst. 2002, 94:422-429.
19. Souza R.F., Shewmake K., Beer D.G., Cryer B., Spechler S.J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000, 60:5767-5772.
20. Shureiqi I., Xu X., Chen D., Lotan R., Morris J.S., Fischer S.M., Lippman S.M. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res. 2001, 61:4879-4884.
21. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53:1322-1327.
22. Funkhouser E.M., Sharp G.B. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995, 76:1116-1119.
23. Corley D.A., Kerlikowske K., Verma R., Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
24. Abnet C., Freedman N., Kamangar F., Leitzmann M., Hollenbeck A., Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br. J. Cancer 2009, 100:551-557.
25. Vaughan T.L., Dong L.M., Blount P.L., Ayub K., Odze R.D., Sanchez C.A., Rabinovitch P.S., Reid B.J. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005, 6:945.
26. Liao L.M., Vaughan T.L., Corley D.A., Cook M.B., Casson A.G., Kamangar F., Abnet C.C., Risch H.A., Giffen C., Freedman N.D., Chow W.H., Sadeghi S., Pandeya N., Whiteman D.C., Murray L.J., Bernstein L., Gammon M.D., Wu A.H. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012, 142:442-452. e445; quiz e422-443.
27. Lindblad M., Lagergren J., Rodríguez L.A.G. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14:444-450.
28. Govindan R., McLeod H., Mantravadi P., Fineberg N., Helft P., Kesler K., Hanna N., Ansari R., Fox E. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology 2004, 18:18-21.
29. Altorki N.K., Christos P., Port J.L., Lee P.C., Mirza F., Spinelli C., Keresztes R., Beneck D., Paul S., Stiles B.M. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J. Thorac. Oncol. 2011, 6:1121.
30. Dawson S., Michael M., Biagi J., Foo K., Jefford M., Ngan S., Leong T., Hui A., Milner A., Thomas R.J. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest. New Drugs 2007, 25:123-129.
31. Tuynman J.B., Buskens C.J., Kemper K., ten Kate F.J., Offerhaus G.J.A., Richel D.J., van Lanschot J.J.B. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann. Surg. 2005, 242:840.
32. Rothwell P.M., Fowkes F.G.R., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
33. Heath E.I., Canto M.I., Piantadosi S., Montgomery E., Weinstein W.M., Herman J.G., Dannenberg A.J., Yang V.W., Shar A.O., Hawk E. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J. Natl. Cancer Inst. 2007, 99:545-557.
34. Gatenby P.A., Ramus J.R., Caygill C.P., Winslet M.C., Watson A. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Eur. J. Cancer Prev. 2009, 18:381.
35. Veldhuyzen v.Z.S., Sherman P. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. CMAJ 1994, 150:177.
36. Ohata H., Kitauchi S., Yoshimura N., Mugitani K., Iwane M., Nakamura H., Yoshikawa A., Yanaoka K., Arii K., Tamai H. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer 2004, 109:138-143.
37. Ristimäki A., Honkanen N., Jänkälä H., Sipponen P., Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997, 57:1276-1280.
38. Saukkonen K., Nieminen O., van Rees B., Vilkki S., Härkönen M., Juhola M., Mecklin J.-P., Sipponen P., Ristimäki A. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin. Cancer Res. 2001, 7:1923-1931.
39. Tanaka T., Kojima T., Yoshimi N., Sugie S., Mori H. Inhibitory effect of the non-steroidal anti-inflammatory drug, indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis 1991, 12:1949-1952.
40. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E.S., Takei Y., Nagano K., Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. Gastrointest Liver Physiol. 1998, 274:G1061-G1067.
41. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Murata H., Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J. Clin. Gastroenterol. 1998, 27:S47-S52.
42. Zhou X.M., Wong B.C.Y., Fan X.M., Zhang H.B., Lin M.C.M., Kung H.F., Lam S.K. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 2001, 22:1393-1397.
43. Farrow D.C., Vaughan T.L., Hansten P.D., Stanford J.L., Risch H.A., Gammon M.D., Chow W.-H., Dubrow R., Ahsan H., Mayne S.T. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1998, 7:97-102.
44. Zaridze D., Borisova E., Maximovitch D., Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int. J. Cancer 1999, 82:473-476.
45. Wang W.H., Huang J.Q., Zheng G.F., Lam S.K., Karlberg J., Wong B.C.-Y. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2003, 95:1784-1791.
46. Hansen S., Melby K., Aase S., Jellum E., Vollset S. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer: a nested case-control study. Scand. J. Gastroenterol. 1999, 34:353-360.
47. Akre K., Ekström A., Signorello L., Hansson L., Nyren O. Aspirin and risk for gastric cancer: a population-based case - control study in Sweden. Br. J. Cancer 2001, 84:965.
48. Tian W., Zhao Y., Liu S., Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur. J. Cancer Prev. 2010, 19:288-298.
49. Wu C.-Y., Wu M.-S., Kuo K.N., Wang C.-B., Chen Y.-J., Lin J.-T. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori - infected patients. J. Clin. Oncol. 2010, 28:2952-2957.
50. Sørensen H.T., Friis S., Nørgård B., Mellemkjaer L., Blot W., McLaughlin J., Ekbom A., Baron J. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br. J. Cancer 2003, 88:1687-1692.
51. Iwata C., Kano M.R., Komuro A., Oka M., Kiyono K., Johansson E., Morishita Y., Yashiro M., Hirakawa K., Kaminishi M. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 2007, 67:10181-10189.
52. Wong B.C., Zhang L., Ma J.-l., Pan K.-f., Li J.-y., Shen L., Liu W.-d., Feng G.-s., Zhang X.-d., Li J. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012, 61:812-818.
53. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., Soslow R.A., Masferrer J.L., Woerner B.M., Koki A.T. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999, 59:987-990.
54. Yip-Schneider M.T., Barnard D.S., Billings S.D., Cheng L., Heilman D.K., Lin A., Marshall S.J., Crowell P.L., Marshall M.S., Sweeney C.J. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000, 21:139-146.
55. Kokawa A., Kondo H., Gotoda T., Ono H., Saito D., Nakadaira S., Kosuge T., Yoshida S. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001, 91:333-338.
56. Chu J., Lloyd F.L., Trifan O.C., Knapp B., Rizzo M.T. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer1. Mol. Cancer Ther. 2003, 2:1-7.
57. Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., Sinicrope F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999, 59:4356-4362.
58. El-Rayes B.F., Ali S., Sarkar F.H., Philip P.A. Cyclooxygenase-2-dependent and-independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 2004, 3:1421-1426.
59. Ouyang N., Williams J.L., Tsioulias G.J., Gao J., Iatropoulos M.J., Kopelovich L., Kashfi K., Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 2006, 66:4503-4511.
60. Wei D., Wang L., He Y., Xiong H.Q., Abbruzzese J.L., Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 2004, 64:2030-2038.
61. Zhou H., Huang L., Sun Y., Rigas B. Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling. Cancer Lett. 2009, 273:292-299.
62. Funahashi H., Satake M., Dawson D., Huynh N.-A., Reber H.A., Hines O.J., Eibl G. Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007, 67:7068-7071.
63. Anderson K.E., Johnson T.W., Lazovich D., Folsom A.R. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J. Natl. Cancer Inst. 2002, 94:1168-1171.
64. Bradley M., Hughes C., Cantwell M., Napolitano G., Murray L. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br. J. Cancer 2010, 102:1415-1421.
65. Tan X.-L., Lombardo K.M.R., Bamlet W.R., Oberg A.L., Robinson D.P., Anderson K.E., Petersen G.M. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev. Res. 2011, 4:1835-1841.
66. Schernhammer E.S., Kang J.-H., Chan A.T., Michaud D.S., Skinner H.G., Giovannucci E., Colditz G.A., Fuchs C.S. A prospective study of aspirin use and the risk of pancreatic cancer in women. J. Natl. Cancer Inst. 2004, 96:22-28.
67. Larsson S.C., Giovannucci E., Bergkvist L., Wolk A. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2561-2564.
68. Bonifazi M., Gallus S., Bosetti C., Polesel J., Serraino D., Talamini R., Negri E., La Vecchia C. Aspirin use and pancreatic cancer risk. Eur. J. Cancer Prev. 2010, 19:352-354.
69. Milella M., Gelibter A., Cosimo S.D., Bria E., Ruggeri E.M., Carlini P., Malaguti P., Pellicciotta M., Terzoli E., Cognetti F. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004, 101:133-138.
70. Ferrari V., Valcamonico F., Amoroso V., Simoncini E., Vassalli L., Marpicati P., Rangoni G., Grisanti S., Tiberio G.A., Nodari F. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother. Pharmacol. 2006, 57:185-190.
71. Pino M.S., Milella M., Gelibter A., Sperduti I., De Marco S., Nuzzo C., Bria E., Carpanese L., Ruggeri E.M., Carlini P. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009, 76:254-261.
72. El-Rayes B.F., Zalupski M.M., Shields A.F., Ferris A.M., Vaishampayan U., Heilbrun L.K., Venkatramanamoorthy R., Adsay V., Philip P.A. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest. New Drugs 2005, 23:583-590.
73. Dragovich T., Burris H., Loehrer P., Von Hoff D.D., Chow S., Stratton S., Green S., Obregon Y., Alvarez I., Gordon M. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am. J. Clin. Oncol. 2008, 31:157-162.
74. Koga H., Sakisaka S., Ohishi M., Kawaguchi T., Taniguchi E., Sasatomi K., Harada M., Kusaba T., Tanaka M., Kimura R. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Hepatology 1999, 29:688-696.
75. Shiota G., Okubo M., Noumi T., Noguchi N., Oyama K., Takano Y., Yashima K., Kishimoto Y., Kawasaki H. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999, 46:407.
76. Kondo M., Yamamoto H., Nagano H., Okami J., Ito Y., Shimizu J., Eguchi H., Miyamoto A., Dono K., Umeshita K. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res. 1999, 5:4005-4012.
77. Cheng J., Imanishi H., Iijima H., Shimomura S., Yamamoto T., Amuro Y., Kubota A., Hada T. Expression of cyclooxygenase 2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol. Res. 2002, 23:185-195.
78. Leng J., Han C., Demetris A.J., Michalopoulos G.K., Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through AKT activation: evidence for AKT inhibition in celecoxib-induced apoptosis. Hepatology 2003, 38:756-768.
79. Cui W., Yu C.-H., Hu K.-Q. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin. Cancer Res. 2005, 11:8213-8221.
80. Kern M.A., Haugg A.M., Koch A.F., Schilling T., Breuhahn K., Walczak H., Fleischer B., Trautwein C., Michalski C., Schulze-Bergkamen H. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 2006, 66:7059-7066.
81. Fredriksson L., Herpers B., Benedetti G., Matadin Q., Puigvert J.C., de Bont H., Dragovic S., Vermeulen N.P., Commandeur J.N., Danen E. Diclofenac inhibits tumor necrosis factor-α-induced nuclear factor-κB activation causing synergistic hepatocyte apoptosis. Hepatology 2011, 53:2027-2041.
82. Abiru S., Nakao K., Ichikawa T., Migita K., Shigeno M., Sakamoto M., Ishikawa H., Hamasaki K., Nakata K., Eguchi K. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 2003, 35:1117-1124.
83. Cheng A., Chan H., Leung W.K., Wong N., Johnson P.J., Sung J. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int. J. Cancer 2003, 23:113.
84. Rahman M.A., Dhar D.K., Masunaga R., Yamanoi A., Kohno H., Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res. 2000, 60:2085-2089.
85. Sitia G., Aiolfi R., Di Lucia P., Mainetti M., Fiocchi A., Mingozzi F., Esposito A., Ruggeri Z.M., Chisari F.V., Iannacone M. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc. Natl. Acad. Sci. USA 2012, 109:E2165-E2172.
86. Yamamoto H., Kondo M., Nakamori S., Nagano H. K.i. Wakasa, Y. Sugita, J. Chang-de, S. Kobayashi, B. Damdinsuren, K. Dono, JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 2003, 125:556-571.
87. Sahasrabuddhe V.V., Gunja M.Z., Graubard B.I., Trabert B., Schwartz L.M., Park Y., Hollenbeck A.R., Freedman N.D., McGlynn K.A. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J. Natl. Cancer Inst. 2012, 104:1808-1814.
88. Coogan P.F., Rosenberg L., Palmer J.R., Strom B.L., Zauber A.G., Stolley P.D., Shapiro S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol. Biomarkers Prev. 2000, 9:119-123.
89. Eberhart C.E., Coffey R., Radhika A., Giardiello F., Ferrenbach S., DuBois R. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183.
90. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res. 1995, 55:3785-3789.
91. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998, 58:362-366.
92. Chen W.S., Wei S.J., Liu J.M., Hsiao M., Kou-Lin J., Yang W.K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int. J. Cancer 2001, 91:894-899.
93. Cianchi F., Cortesini C., Bechi P., Fantappiè O., Messerini L., Vannacci A., Sardi I., Baroni G., Boddi V., Mazzanti R. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001, 121:1339.
94. Thun M.J., Namboodiri M.M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1991, 325:1593-1596.
95. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., Willett W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Int. Med. 1994, 121:241-246.
96. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willett W.C., Speizer F.E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 1995, 333:609-614.
97. Cook N.R., Lee I.M., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., Hennekens C.H., Buring J.E. Low-dose aspirin in the primary prevention of cancer: the women's health study: a randomized controlled trial. JAMA 2005, 294:47-55.
98. Flossmann E., Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613.
99. Rothwell P.M., Wilson M., Elwin C.-E., Norrving B., Algra A., Warlow C.P., Meade T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
100. Chan A.T., Ogino S., Fuchs C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 2007, 356:2131-2142.
101. Burn J., Bishop D.T., Mecklin J.-P., Macrae F., Möslein G., Olschwang S., Bisgaard M.-L., Ramesar R., Eccles D., Maher E.R. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med. 2008, 359:2567-2578.
102. Burn J., Gerdes A.-M., Macrae F., Mecklin J.-P., Moeslein G., Olschwang S., Eccles D., Evans D.G., Maher E.R., Bertario L. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011.
103. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J.A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993, 328:1313-1316.
104. Burn J., Bishop D.T., Chapman P.D., Elliott F., Bertario L., Dunlop M.G., Eccles D., Ellis A., Evans D.G., Fodde R. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev. Res. 2011, 4:655-665.
105. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., Snover D.C., Church T.R., Allen J.I., Beach M., Beck G.J., Bond J.H., Byers T., Greenberg E.R., Mandel J.S., Marcon N., Mott L.A., Pearson L., Saibil F., van Stolk R.U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003, 348:891-899.
106. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J.M., Karp D.D., Loprinzi C.L., Steinbach G., Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003, 348:883-890.
107. Chan A.T., Giovannucci E.L., Schernhammer E.S., Colditz G.A., Hunter D.J., Willett W.C., Fuchs C.S. A prospective study of aspirin use and the risk for colorectal adenoma. Ann. Int. Med. 2004, 140:157.
108. Chan A.T., Giovannucci E.L., Meyerhardt J.A., Schernhammer E.S., Curhan G.C., Fuchs C.S. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005, 294:914-923.
109. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342:1946-1952.
110. Arber N., Eagle C.J., Spicak J., Rácz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355:885-895.
111. Baron J.A., Sandler R.S., Bresalier R.S., Quan H., Riddell R., Lanas A., Bolognese J.A., Oxenius B., Horgan K., Loftus S. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131:1674-1682.
112. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355:873-884.
113. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302:649-658.
114. Liao X., Lochhead P., Nishihara R., Morikawa T., Kuchiba A., Yamauchi M., Imamura Y., Qian Z.R., Baba Y., Shima K., Sun R., Nosho K., Meyerhardt J.A., Giovannucci E., Fuchs C.S., Chan A.T., Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 2012, 367:1596-1606.
115. Din F.V., Theodoratou E., Farrington S.M., Tenesa A., Barnetson R.A., Cetnarskyj R., Stark L., Porteous M.E., Campbell H., Dunlop M.G. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010, 59:1670-1679.
116. Bastiaannet E., Sampieri K., Dekkers O., de Craen A., van Herk-Sukel M., Lemmens V., van den Broek C., Coebergh J., Herings R., van de Velde C. Use of Aspirin postdiagnosis improves survival for colon cancer patients. Br. J. Cancer 2012, 106:1564-1570.
117. Walker A., Grainge M., Card T. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br. J. Cancer 2012.
118. Algra A.M., Rothwell P.M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012.
119. Izzo J.G., Ajani J.A. Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2. J. Clin. Oncol. 2007, 25:4865-4867.
120. Tahara T., Shibata T., Nakamura M., Yamashita H., Yoshioka D., Okubo M., Maruyama N., Kamano T., Kamiya Y., Fujita H. Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. Dig. Dis. Sci. 2010, 55:54-59.
121. Tahara T., Shibata T., Yamashita H., Nakamura M., Yoshioka D., Okubo M., Hirata I., Arisawa T. Chronic nonsteroidal anti-inflammatory drug (NSAID) use suppresses multiple CpG islands hyper methylation (CIHM) of tumor suppressor genes in the human gastric mucosa. Cancer Sci. 2009, 100:1192-1197.
122. Saito Y., Suzuki H., Imaeda H., Matsuzaki J., Hirata K., Tsugawa H., Hibino S., Kanai Y., Saito H., Hibi T. The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. Int. J. Cancer 2013, 132:1751-1760.
123. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
124. Hao X., Bishop A.E., Wallace M., Wang H., Willcocks T.C., Maclouf J., Polak J.M., Knight S., Talbot I.C. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J. Pathol. 1999, 187:295-301.
125. Tuynman J.B., Vermeulen L., Boon E.M., Kemper K., Zwinderman A.H., Peppelenbosch M.P., Richel D.J. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008, 68:1213-1220.
126. Bos C.L., Kodach L.L., van den Brink G.R., Diks S.H., van Santen M.M., Richel D.J., Peppelenbosch M.P., Hardwick J.C. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. Oncogene 2006, 25:6447-6456.
127. Gao J., Liu X., Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. USA 2005, 102:17207-17212.
128. Greenhough A., Wallam C.A., Hicks D.J., Moorghen M., Williams A.C., Paraskeva C. The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE2 signalling in colorectal adenoma cells. Oncogene 2010, 29:3398-3410.
129. Sun Y., Tang X.M., Half E., Kuo M.T., Sinicrope F.A. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002, 62:6323-6328.
130. Heslin M.J., Hawkins A., Boedefeld W., Arnoletti J.P., Frolov A., Soong R., Urist M.M., Bland K.I. Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann. Surg. 2005, 241:941.
131. Deguchi A., Xing S.W., Shureiqi I., Yang P., Newman R.A., Lippman S.M., Feinmark S.J., Oehlen B., Weinstein I.B. Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. Cancer Res. 2005, 65:8442-8447.
132. Wu J., Xia H.H.X., Tu S.P., Lin M.C.M., Kung H.F., Lam S.K., Wong B.C.Y. 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis 2003, 24:243-247.